Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
United States drugmaker Merck & Co Inc has begun recruiting participants into its early-stage COVID-19 vaccine study, according to the government database clinicaltrials.gov.
The phase 1/2 trial, which is based in Belgium, intends to recruit 260 healthy participants to check the experimental vaccine V591, which it gained access to as a member of its May deal for Austrian vaccine maker Themis Bioscience.
The vaccine is based on a modified measles virus which delivers bits of the new coronavirus into the body to avoid COVID-19.
Merck is late to join the race to develop a safe and effective vaccine to the fast-spreading respiratory illness as rivals Pfizer Inc, AstraZeneca Plc and Moderna Inc are already in late-stage testing.
The drugmaker is also collaborating with research non-profit IAVI on a second vaccine candidate that employs the same technology as Merck’s Ebola vaccine, ERVEBO.
Earlier this month, Chief Executive Kenneth Frazier had stated the second candidate is very likely to begin trials later this year.
